DSCM
PHAT icon

Divisadero Street Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Divisadero Street Capital Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-662,312
Closed -$11M – 127
2025
Q4 		$11M Buy
+662,312
New +$9.46M 0.51% 39

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Divisadero Street Capital Management's PHAT Position: Q1 2026 in Review

Divisadero Street Capital Management sold out of Phathom Pharmaceuticals (PHAT) in Q1 2026, closing a stake of 662,312 shares — an estimated $11M sold.

Divisadero Street Capital Management first reported a position in PHAT in Q4 2025 and held it in 1 quarter. The position peaked at $11M in Q4 2025. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Divisadero Street Capital Management reported no remaining Phathom Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Divisadero Street Capital Management sold 662,312 Phathom Pharmaceuticals shares in Q1 2026, an estimated $11M.
  • Divisadero Street Capital Management first reported a position in Phathom Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Divisadero Street Capital Management's Phathom Pharmaceuticals position peaked at $11M in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Divisadero Street Capital Management's 13F filing for Q1 2026, filed 15 May 2026.